Singh L, Menzies R, Tricklebank M D
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.
Eur J Pharmacol. 1990 Sep 4;186(1):129-32. doi: 10.1016/0014-2999(90)94069-a.
Using a two-lever operant drug discrimination paradigm, rats have been trained to discriminate between the administration of saline and R-(+)-HA-966 (R-(+)-3-amino-1-hydroxypyrrolid-2-one, 30 mg/kg i.p.) an antagonist at the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor/ion channel complex. Drug-appropriate responding was not induced in stimulus generalisation experiments when the non-competitive NMDA receptor antagonist, phencyclidine (PCP, 1-8 mg/kg i.p.) was substituted for (+)-HA-966. Similarly, (+)-HA-966 (6-50 mg/kg i.p.) did not induce drug-appropriate responding in animals trained to discriminate PCP (3 mg/kg i.p.) from saline. The results suggest that the behavioural profile of compounds attenuating the actions of NMDA via blockade of the glycine modulatory site may be substantially different from those acting at the ion channel of the NMDA receptor complex.
使用双杠杆操作性药物辨别范式,已训练大鼠区分生理盐水给药和R-(+)-HA-966(R-(+)-3-氨基-1-羟基吡咯烷-2-酮,腹腔注射30mg/kg),后者是N-甲基-D-天冬氨酸(NMDA)受体/离子通道复合物甘氨酸调节位点的拮抗剂。在刺激泛化实验中,当非竞争性NMDA受体拮抗剂苯环利定(PCP,腹腔注射1-8mg/kg)替代(+)-HA-966时,未诱导出药物相关反应。同样,(+)-HA-966(腹腔注射6-50mg/kg)在训练区分PCP(腹腔注射3mg/kg)和生理盐水的动物中也未诱导出药物相关反应。结果表明,通过阻断甘氨酸调节位点来减弱NMDA作用的化合物的行为特征可能与作用于NMDA受体复合物离子通道的化合物有很大不同。